NAMPT inhibitor-linker 2, a drug-linker conjugate for antibody-drug conjugates (ADCs), comprises an NAMPT inhibitor payload and a linker. When combined with an anti-c-Kit monoclonal antibody to form ADC-4, it demonstrates potent efficacy against c-Kit expressing cell lines, including GIST-T1 and NCI-H526, with IC50 values of <7 pM and 40 pM, respectively.

MC-Val-Cit-PAB-MMAF is an antibody-drug conjugate (ADC) component that exhibits antitumor properties through the action of the tubulin inhibitor, monomethyl auristatin F (MMAF), which is connected by a cathepsin-cleavable linker, MC-Val-Cit-PAB.

Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) is a drug-linker conjugate for antibody-drug conjugates (ADCs) that combines the ADC linker (Acetylene-linker-Val-Cit-PABC) with the potent tubulin inhibitor MMAE.

Mal-(CH2)5-Val-Cit-PAB-Eribulin is a potent antitumor ADC drug-linker conjugate that utilizes Eribulin, an anti-microtubule agent, connected through the Mal-(CH2)5-Val-Cit-PAB linker.

MC-Val-Cit-PAB-carfilzomib is a potent antitumor drug-linker conjugate for antibody-drug conjugates (ADC), comprising the irreversible proteasome inhibitor carfilzomib, connected through the ADC linker MC-Val-Cit-PAB.

DBCO-PEG4-VC-PAB-MMAE, an ADC linker comprising DBCO-PEG4-VC-PAB coupled with the tubulin polymerization inhibitor MMAE, serves as a key component in the formulation of antibody-drug conjugates (ADCs). MMAE, a synthetic derivative of dolastatin 10, inhibits tubulin polymerization, acting as a potent mitotic inhibitor.

Mal-GGFG-PAB-MMAE (Compound 8) 为一种药物-连接子复合物，由有丝分裂抑制剂 MMAE 和连接子 Mal-GGFG-PAB 组成。此化合物可用于合成抗体药物偶联物。

Val-Cit-PAB-Exatecan TFA(Val-Cit-PAB-DX8951)是一种抗体-药物偶联物 (ADC) 的关键组成部分,其结构包括 DNA 拓扑异构酶 I (DX-8951) 活性杂化分子和一种由组织蛋白酶可降解的连接子组成.

DBCO-β-Glu-PEG12-Exatecan（化合物107）是一种拓扑异构酶I的抑制剂。它可以作为药物-连接子偶联物，用于抗体药物偶联物（ADC）分子的合成。